Abbott Laboratories $ABT Shares Sold by UniSuper Management Pty Ltd

UniSuper Management Pty Ltd cut its holdings in shares of Abbott Laboratories (NYSE:ABT) by 3.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 581,504 shares of the healthcare product maker’s stock after selling 19,587 shares during the period. UniSuper Management Pty Ltd’s holdings in Abbott Laboratories were worth $72,857,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Nia Impact Advisors LLC boosted its position in shares of Abbott Laboratories by 2.2% during the 2nd quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock valued at $504,000 after acquiring an additional 79 shares during the last quarter. American National Bank of Texas boosted its position in shares of Abbott Laboratories by 2.4% during the 4th quarter. American National Bank of Texas now owns 3,408 shares of the healthcare product maker’s stock valued at $427,000 after acquiring an additional 79 shares during the last quarter. Connable Office Inc. boosted its position in shares of Abbott Laboratories by 0.5% during the 3rd quarter. Connable Office Inc. now owns 15,042 shares of the healthcare product maker’s stock valued at $2,015,000 after acquiring an additional 81 shares during the last quarter. Park Place Capital Corp boosted its position in shares of Abbott Laboratories by 11.0% during the 4th quarter. Park Place Capital Corp now owns 815 shares of the healthcare product maker’s stock valued at $102,000 after acquiring an additional 81 shares during the last quarter. Finally, Lantern Wealth Advisors LLC boosted its position in shares of Abbott Laboratories by 1.7% during the 3rd quarter. Lantern Wealth Advisors LLC now owns 5,028 shares of the healthcare product maker’s stock valued at $674,000 after acquiring an additional 84 shares during the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories Stock Up 0.5%

NYSE:ABT opened at $89.65 on Friday. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $139.06. The company has a market cap of $156.14 billion, a price-to-earnings ratio of 25.11, a price-to-earnings-growth ratio of 1.49 and a beta of 0.63. The stock has a fifty day simple moving average of $91.75 and a 200-day simple moving average of $108.12. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The business had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. During the same period last year, the company earned $1.09 earnings per share. The business’s revenue for the quarter was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Analysts anticipate that Abbott Laboratories will post 5.48 EPS for the current year.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau bought 2,200 shares of the firm’s stock in a transaction dated Thursday, April 23rd. The stock was acquired at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the transaction, the chief financial officer owned 2,200 shares in the company, valued at $201,300. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Daniel J. Starks bought 10,000 shares of the firm’s stock in a transaction dated Monday, April 27th. The shares were acquired at an average price of $92.65 per share, with a total value of $926,500.00. Following the completion of the transaction, the director owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their position. The disclosure for this purchase is available in the SEC filing. 0.46% of the stock is currently owned by company insiders.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott helped lead the first close of Star51 Capital’s inaugural medtech venture fund, highlighting its commitment to healthcare innovation and potential future deal flow in medtech. Star51 Capital Announces First Close of Medtech Venture Fund
• Positive Sentiment: Abbott received more support for its diabetes and cancer diagnostics growth story, including CE Mark approval for Libre Duo and updated colorectal cancer screening guidance favoring its tests, which could support long-term revenue growth. Abbott Diabetes And Cancer Milestones Contrast With Prolonged Share Price Weakness
• Positive Sentiment: Abbott’s expanded agreement with MiniMed to commercialize dual glucose-ketone sensors adds another growth avenue in diabetes care and strengthens its connected-device strategy. This is Why Abbott Laboratories (ABT) is One of the Best Deep Value Stock to Invest In
• Neutral Sentiment: ABBT was noted as a trending stock on Zacks, suggesting elevated investor attention but not a clear fundamental catalyst by itself. Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: Analysts on balance were slightly more cautious, with Erste Group trimming its FY2027 EPS estimate only marginally to $6.04 from $6.05, a small change that does not signal a major shift in outlook. Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Cartesian Therapeutics (RNAC) and Abbott Laboratories (ABT)
• Negative Sentiment: Some investors also pointed to weakness in the stock itself, with recent trading showing ABT underperforming the broader market, suggesting sentiment remains pressured despite the positive product news. Abbott (ABT) Dips More Than Broader Market: What You Should Know

Analysts Set New Price Targets

A number of research firms have recently commented on ABT. BTIG Research reiterated a “buy” rating and set a $131.00 target price on shares of Abbott Laboratories in a research report on Monday, April 27th. Barclays lowered their price target on Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating for the company in a research report on Monday, April 20th. Raymond James Financial lowered their price target on Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Piper Sandler lowered their price target on Abbott Laboratories from $135.00 to $115.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Finally, Mizuho lowered their price target on Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating for the company in a research report on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average target price of $119.09.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.